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Abstract
Soft tissue sarcomas are a heterogeneous group of malig-
nancies arising from mesenchymal tissues. A large num-
ber of new therapies are being evaluated in patients with 
sarcomas, and consensus criteria defining treatment 
responses are essential for comparison of results from 
studies completed by different research groups. The 
1979 World Health Organization (WHO) handbook set 
forth operationally defined criteria for response evalu-
ation in solid tumors that were updated in 2000 with 
the publication of the Response Evaluation Criteria 
in Solid Tumors (RECIST). There have been signifi-
cant advances in tumor imaging, however, that are not 
reflected in the RECIST. For example, computed tomog-
raphy (CT) slice thickness has been reduced from 10 mm 
to ≤2.5 mm, allowing for more reproducible and accu-
rate measurement of smaller lesions. Combination of 
imaging techniques, such as positron emission tomogra-
phy with fluorine-18-fluorodeoxyglucose (18FDG-PET) 
and CT can provide investigators and clinicians with 
both anatomical and functional information regard-
ing tumors, and there is now a large body of evidence 
demonstrating the effectiveness of PET/CT and other 
newer imaging methods for the detection and staging 
of tumors as well as early determination of responses to 
therapy. The application of newer imaging methods has 
the potential to decrease both the sample sizes required 
for, and duration of, clinical trials by providing an early 
indication of therapeutic response that is well correlated 
with clinical outcomes, such as time to tumor progres-
sion or overall survival. The results summarized in this 
review support the conclusion that the RECIST and the 
WHO criteria for evaluation of response in solid tumors 
need to be modernized. In addition, there is a current 
need for prospective trials to compare new response cri-
teria with established endpoints and to validate imag-
ing-based response rates as surrogate endpoints for 
clinical trials of new agents for sarcoma and other solid 
tumors. The Oncologist 2008;13(suppl 2):32–40
Introduction
Soft tissue sarcomas are a heterogeneous group of malig-
nancies arising from mesenchymal tissues [1]. Based on the 
Surveillance, Epidemiology, and End Results (SEER) data-
base, nearly 15,000 new cases of sarcoma, both bone and 
soft tissue, are diagnosed in the U.S. each year [2]. Anthra-
cyclines and ifosfamide have been established as the most 
active drugs for the treatment of patients with advanced, 
soft tissue sarcomas of most histologic subtypes, with the 
exception of gastrointestinal stromal tumors (GISTs). How-
ever, after failure of these drugs, patients with advanced 
soft tissue sarcomas have few treatment options [3]. Limita-
tions in current therapeutic options for these tumors have 
prompted the development and evaluation of a very large 
number of new chemotherapeutic and biologic agents for 
their treatment [3].
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Assessment of new therapies for sarcomas requires 
agreement on, and consistent use of, endpoints sensitive 
to the effects of these treatments. Longer survival is the 
generally accepted gold standard for demonstrating clini-
cal benefit of an oncologic therapy. However, a wide range 
of surrogate endpoints has been employed as the basis for 
approving new therapeutic agents [4], and considerable 
controversy exists regarding which endpoints may be most 
appropriate for specific tumors [4]. This review article ana-
lyzes endpoints in oncology clinical trials, with a focus on 
sarcomas. This issue is timely, because there has been con-
siderable evolution in approaches for assessment of these 
tumors and endpoints employed in clinical studies.
Current Issues in Considering Endpoints
The acceptance of new cancer treatments requires demon-
stration of their benefit in clinical trials. Results from these 
studies may be confounded or invalidated by a large number 
of factors, including invalid comparisons in nonrandomized 
studies because of patient selection or stage migration, inad-
equate power of the study (i.e., sample size) to detect clini-
cally meaningful differences in appropriately controlled 
randomized trials, use of multiple comparisons and retro-
spective analyses to make inappropriate conclusions from 
randomized trials, and endpoints that are inappropriate 
for the cancer under study [5]. Thus, documenting benefit 
for a new cancer therapy requires attention to study design 
and data analysis, and particularly to selection of study 
endpoints. Selection of endpoints for studies of new cancer 
therapies may be especially challenging because many of 
them require long-term patient follow-up and thus demand 
long-term studies. This conflicts with pressure to provide 
patients with rapid access to new treatments [6]. It has also 
been noted that there is greater tolerance for agents with 
high toxicity profiles that demonstrate efficacy, particularly 
in cancers where treatment options are limited, and that this 
may result in acceptance of therapies with high risk-to-ben-
efit ratios [7]. The objective of a phase III oncology trial is to 
determine the risk-to-benefit ratio of an experimental agent 
or regimen, compared with a standard treatment [8].
Overall Survival
Overall survival (OS) has traditionally been the gold stan-
dard as the primary endpoint of phase III trials of cancer 
therapies [8]. When a randomized trial clearly demon-
strates that an experimental drug produces a longer OS 
time than with standard therapy, approval is likely [9]. A 
number of advantages are associated with the use of OS as 
an endpoint for clinical trials of cancer therapies. It is objec-
tive and free from ambiguities in interpretation. However, 
it may be confounded by deaths from causes other than the 
patient’s cancer [8, 10]. The survival difference should not 
only be statistically significant but also regarded as clini-
cally significant.
Several additional problems may arise with the use of 
OS as the primary endpoint in an oncology study. The cur-
rent availability of multiple effective lines of systemic or 
local therapy, as well as treatment switching, may obscure 
the impact of the agent under study upon survival in an 
intent-to-treat analysis. In addition, the interval from the end 
of recruitment to primary efficacy analysis for OS is pro-
tracted, such that subsequent studies taking the best therapy 
from the previous trial cannot begin until years after the pre-
vious trial has completed recruitment. Trials based on OS, 
which require a minimum of 5 years to complete, are inevi-
tably lengthy and expensive [10, 11] and inhibit drug devel-
opment, especially in uncommon cancers such as sarcoma. 
Time to Progression and Progression-Free 
Survival
Time to progression (TTP) and progression-free sur-
vival (PFS) time (defined as the time from randomization 
to death or progression, whichever comes first) are also 
used extensively as endpoints in clinical trials of cancer 
therapies. These endpoints are similar except that death is 
included in PFS [8, 10]. Both PFS and TTP are correlated 
with OS in patients with rectal cancer and can be consid-
ered as surrogates for it in this setting [11]. Perhaps the most 
important advantage associated with the use of PFS and 
TTP is that they permit smaller sample sizes and shorter 
study durations. Progression often occurs months to years 
before death, and differences in the efficacies of new drugs 
or therapeutic regimens can be detected with shorter follow-
up. Another advantage of these endpoints is that TTP and 
PFS do not require shrinkage of the tumor mass for detec-
tion of differences between treatments, which may make 
them highly suitable for measuring the benefits of cytostatic 
agents. In addition, disease progression is often the basis for 
a change in therapy and thus has high applicability to clini-
cal practice [9–11]. Most importantly, TTP or PFS after a 
single line of therapy is a direct measure of the benefit from 
that treatment and is not confounded by subsequent events. 
However, both PFS and TTP also have disadvantages 
as surrogate endpoints for OS in clinical trials. The clini-
cal significance of small differences in TTP or PFS may be 
unclear (as in OS), especially when one is evaluating toxic 
treatments, and careful assessment of progression at fre-
quent intervals can be costly and labor-intensive. There are 
also concerns about ascertainment bias in unblinded trials 
and questions about the reliability of modest differences in 
TTP or PFS that are often observed in such studies. Because 
OS is not the primary endpoint in studies employing either 
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PFS or TTP as surrogates, a design to cross over to the inves-
tigational treatment from the standard or placebo arm when 
tumor progression occurs can also be considered. A cross-
over design has the potential to improve patient enrollment 
and patient benefit. However, it is also a weakness in that it 
can dilute the contribution of a survival benefit [10, 11]. 
Response Rates
Response rates are also used to assess efficacy in trials of 
cancer therapies. Response measures have been variously 
defined. However, a complete response (CR) generally 
indicates tumor disappearance, a partial response (PR) 
indicates a >50% reduction in the tumor cross product 
(multiplication of the maximum tumor diameter in the axial 
plane by the largest diameter and its perpendicular dimen-
sion on the same image), and stable disease (SD) indicates 
a <50% reduction to <25% increase in the cross product 
[12]. Advantages associated with the use of these measures 
include the lack of a dilution effect with smaller sample 
sizes, shorter study durations, and tumor shrinkage, which 
is clearly and solely dependent on a therapeutic intervention, 
as spontaneous regressions are quite rare. Disadvantages 
include potential for bias in unblinded studies, variability in 
results across studies and centers within an individual trial 
secondary to differences in criteria and methods of assess-
ment, and the fact that a response to treatment may not nec-
essarily equate with clinical benefit. Response to treatment 
may or may not be a true surrogate for survival [10].
The Need for Redefining Response
The World Health Organization Criteria
Consensus criteria for defining a response to cancer therapy 
are essential for comparison of data from studies carried 
out by different research and clinical trial groups. In 1979, 
the World Health Organization (WHO) handbook set forth 
four specific operationally defined criteria for the codifica-
tion of response evaluation in solid tumors. In this scheme, 
the lesions are measured bidimensionally and the product 
of the greatest tumor diameter and the greatest perpendicu-
lar distance, summed over all measured tumors, is used in 
determining responses. The four response categories were: 
CR, tumor disappearance confirmed at 4 weeks; PR, 50% 
or greater decrease in tumor size confirmed at 4 weeks; no 
change (NC), neither PR nor PD criteria met; and progres-
sive disease (PD), 25% or greater increase in tumor size 
with no CR, PR, or SD documented before increased dis-
ease [13, 14].
Three major problems with these definitions gradu-
ally became apparent with their use in clinical trials [15, 
16]. Methods of integrating the change in tumor size into 
response assessments varied among research groups, 
minimum lesion size and number of lesions documented 
varied from one study to the next, and what constituted PD 
was based on the change in size of a single lesion by some 
researchers and a change in the overall tumor load (includ-
ing measurements of all lesions) by others. The advent of 
new technologies, particularly computed tomography (CT) 
and magnetic resonance imaging (MRI), further confused 
matters with respect to the relevance of volumetric and 
three-dimensional measurements versus bidimensional 
measures in response assessments. The combination of 
all these factors resulted in a situation in which response 
criteria were no longer comparable among research organi-
zations. This was the circumstance that the original WHO 
publication had aimed to avoid.
Response Evaluation Criteria in Solid Tumors
The Response Evaluation Criteria in Solid Tumors 
(RECIST) were developed in response to problems with 
the WHO criteria. The RECIST were published in 2000 
and are a simplification of four other methods of assessing 
solid tumor responses. The RECIST are generally similar 
to the criteria set forth by the 1979 WHO handbook, with 
the major change being that the RECIST employ unidimen-
sional measurements of the sum of the longest diameters of 
tumors in the axial plane instead of the conventional bidi-
mensional WHO method of the product of the longest diam-
eter and that perpendicular to it, summed over all measured 
tumors. The RECIST response categories are: CR, disap-
pearance of tumor sustained for at least 4 weeks; PR, ≥30% 
decrease in tumor sustained for at least 4 weeks; SD, neither 
PR nor PD criteria met; and PD, ≥20% increase with no CR, 
PR, or SD documented before increase of disease [12]. A 
detailed comparison of the WHO criteria and the RECIST 
and their associated guidelines is provided in Table 1 [17].
Potential advantages of the RECIST over the WHO 
criteria [17] include the fact that the RECIST give specific 
size requirements for measurable lesions at baseline, dis-
tinguish target from nontarget lesions, allow the maximum 
number of target lesions to be followed up to a total of 10, 
and provide a baseline tumor burden (smallest sum of lon-
gest diameters from the start of treatment) for determining 
PD. The RECIST also state that all target lesions should be 
measured to determine PD instead of one or more measur-
able lesions [17].
The RECIST are predicated on unidimensional and 
bidimensional measurements being comparable and 
assume metastases are spherical and change proportionally. 
Application of the WHO criteria and RECIST to the same 
patients in 14 studies with a wide range of cancers indicated 
very similar results for all response categories. Results from 
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this analysis indicated that 91.9% of patients evaluated had 
the same date of disease progression with the WHO crite-
ria and RECIST; 7.3% had earlier disease progression with 
the WHO criteria and 0.9% had earlier disease progression 
with the RECIST (Table 2) [12]. This change is important to 
PFS since the PFS time by the RECIST will be longer than 
by the WHO criteria.
Problems with the RECIST in Clinical Trials
The RECIST have been used extensively in clinical trials 
and are generally viewed as an important advancement 
over the criteria provided by the WHO [18]. However, these 
guidelines and criteria do have significant limitations. The 
RECIST are intentionally terse, and this can lead to confu-
sion in how to apply appropriate measurement techniques 
across centers [16]. In addition, unidimensional measure-
ments of the type set forth in the RECIST may not be suit-
Table 1. Comparison of WHO response criteria and RECIST [17]
Characteristic WHO RECIST
Measurability 
of lesions at 
baseline
1. Measurable, bidimensional (product of LD and greatest 
perpendicular diameter)a
1. Measurable, unidimensional (LD only, size with con-
ventional techniques ≥20 mm; spiral computed tomog-
raphy ≥10 mm)
2. Nonmeasurable/evaluable (e.g., lymphangitic pulmo-
nary metastases, abdominal masses)
2. Nonmeasurable: all other lesions, including small 
lesions. Evaluable is not recommended.
Objective 
response
1. Measurable disease (change in sum of products of LDs 
and greatest perpendicular diameters, no maximum num-
ber of lesions specified): CR, disappearance of all known 
disease, confirmed at ≥4 wks; PR, ≥50% decrease from 
baseline, confirmed at ≥4 wks; PD, ≥25% increase of one 
or more lesions, or appearance of new lesions; NC, neither 
PR nor PD criteria met
1. Target lesions (change in sum of LDs, maximum of 
5 per organ up to 10 total [more than one organ]): CR, 
disappearance of all target lesions, confirmed at ≥4 
wks; PR, ≥30% decrease from baseline, confirmed at 
4 wks; PD, ≥20% increase over smallest sum observed, 
or appearance of new lesions; SD, neither PR nor PD 
criteria met
2. Nonmeasurable disease: CR, disappearance of all 
known disease, confirmed at ≥4 wks; PR, estimated 
decrease of ≥50%, confirmed at ≥4 wks; PD, estimated 
increase of ≥25% in existent lesions or appearance of new 
lesions; NC, neither PR nor PD criteria met
2. Nontarget lesions: CR, disappearance of all target 
lesions and normalization of tumor markers, confirmed 
at ≥4 wks; PD, unequivocal progression of nontarget 
lesions, or appearance of new lesions; non-PD: persis-
tence of one or more nontarget lesions and/or tumor 
markers above normal limits
Overall 
response
1. Best response recorded in measurable disease 1. Best response recorded in measurable disease from 
treatment start to disease progression or recurrence
2. NC in nonmeasurable lesions will reduce a CR in mea-
surable lesions to an overall PR
2. Non-PD in nontarget lesion(s) will reduce a CR in tar-
get lesion(s) to an overall PR
3. NC in nonmeasurable lesions will not reduce a PR in 
measurable lesions
3. Non-PD in nontarget lesion(s) will not reduce a PR in 
target lesion(s)
Duration of 
response
1. CR: from date CR criteria first met; to date PD first 
noted
1. Overall CR: from date CR criteria first met; to date 
recurrent disease first noted
2. Overall response: from date of treatment start; to date 
PD first noted
2. Overall response: from date CR or PR criteria first 
met (whichever status came first); to date recurrent dis-
ease or PD first noted
3. In patients who only achieve a PR, only the period of 
overall response should be recorded
3. SD: from date of treatment start; to date PD first noted
aLesions that can only be measured unidimensionally are considered to be measurable (e.g., mediastinal adenopathy, malignant 
hepatomegaly).
Abbreviations: CR, complete response; LD, longest diameter; NC, no change; PD, progressive disease; PR, partial response; 
RECIST, Response Evaluation Criteria in Solid Tumors; SD, stable disease; WHO, World Health Organization.
Table 2. Proportions of patients with disease progression by 
the WHO criteria and the RECIST [12]
n of 
patients
%
Total n of progressors 234 100
Progression by appearance of new lesionsa 118 50
Progression by increase in pre-existing 
measurable disease
116 50
Same date of disease progression by WHO 
criteria and RECIST
215 91.9
Different date of disease progression 19 8.1
Earlier PD with WHO criterion 17 7.3
Earlier PD with unidimensional criterion 2 0.9
aAlso includes a few patients with PD because of a marked 
increase of nonmeasurable disease.
Abbreviations: PD, progressive disease; RECIST, Response 
Evaluation Criteria in Solid Tumors; WHO, World Health 
Organization.
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able for all tumor types, most notably those with nonspheri-
cal growth patterns (e.g., malignant pleural mesothelioma) 
[19–22]. Definition of target lesions may also limit the util-
ity of the RECIST. Target lesions defined by the RECIST 
may not represent burden of disease [23], and changes in 
tumor characteristics may confound evaluation (e.g., pleu-
ral effusions in lung cancer [24]).
There are also limitations of the RECIST with respect 
to determination of disease progression. Response assess-
ment as measured by the RECIST has been shown to have 
some discrepancies with WHO-determined responses. 
These appear to occur most often at the PR–SD and SD–PD 
“borders.” This difference may be problematic when new 
experimental therapies are compared with conventional 
agents whose response rates have been established in his-
torical trials. The apparent lower rate of disease progression 
with the RECIST may mean that more patients remain on 
therapy, and the percentages of patients with SD thus need 
to be interpreted with caution [25]. 
The RECIST also ignore the fact that changes in tumor 
size may not be directly correlated with disease progression 
in all therapeutic situations. Qualitative changes in tumors 
(e.g., myxoid degeneration in GIST) may not be reflected 
in tumor measurements, and this can result in erroneous 
classification of the response to treatment. Standard ana-
tomic imaging techniques are often inadequate for evaluat-
ing malignancies, particularly when monitoring treatment 
responses for agents that do not cause tumor shrinkage (i.e., 
cytostatic agents) or for slow-progressing cancers or those 
malignancies that metastasize diffusely [26]. Thus, mor-
phologic evaluation based solely on one- or two-dimen-
sional measurements may not directly reflect biological 
changes in tumors associated with either the disease itself 
or its treatment [27]. Moreover, anatomical changes in the 
tumor as described by the RECIST may be detected later 
than functional changes in some circumstances (e.g., in 
GISTs treated with imatinib) [18]. The use of a primary 
tumor for response assessment, if the tumor is localized in 
a hollow organ (e.g., the esophagus), also makes measure-
ments based on the RECIST difficult [18].
Finally, it is important to remember that the RECIST 
were developed on the basis of discussions carried out in 
the 1990s and published in 2000. As a result, they do not 
reflect many advances in imaging technology that have 
occurred over the past decade. Newer imaging and image-
processing modalities may allow changes not considered in 
the RECIST to be included in revised response criteria [28]. 
For example, a comparison of relative values of manual 
unidimensional measurements and automated volumetry 
with multidetector-row computed tomography (MDCT) 
for longitudinal treatment response assessment in patients 
with pulmonary metastases indicated that MDCT provided 
better reproducibility of response evaluation and should 
be preferred over manual measurements in these patients 
[28]. The following section further explores the application 
of newer imaging technologies in assessing the efficacy of 
therapies for solid tumors.
Imaging-Based Evaluation of Response to 
Cancer Therapy
Great advances in image acquisition and processing tech-
niques are improving both staging of solid tumors for 
treatment planning and evaluation of new therapies. Sur-
rogate markers of tumor response are also being developed 
with the use of functional imaging techniques that pro-
vide greater insight into tumor responses to therapy (e.g., 
changes in tumor perfusion, permeability, blood volume, 
and oxygenation). Combination of imaging techniques, 
such as positron emission tomography (PET) and computed 
tomography (CT), can provide investigators and clinicians 
with both anatomical and functional information. There 
is now substantial evidence that the use of PET with fluo-
rine-18-fluorodeoxyglucose (18FDG-PET), particularly in 
conjunction with CT, can improve the accuracy of cancer 
staging with a high sensitivity for detecting small-volume 
disease [29]. The application of newer imaging methods that 
permit more rapid and precise evaluation of tumors has the 
potential to decrease both the sample sizes required for and 
duration of clinical trials by providing an early indication 
of therapeutic response that is well correlated with clinical 
outcomes (e.g., OS) for chemo- and radiotherapy [26]. The 
use of these new modalities and advances in transmission, 
storage, quality assurance, and analysis of images could 
streamline clinical trials of new treatments and accelerate 
new drug approvals [26].
CT
As noted above, the RECIST for evaluating responses to 
treatment have been criticized because they do not reflect 
biological changes in solid tumors induced by new targeted 
therapies and thus may provide misleading results. Modi-
fied objective criteria using a combination of tumor size and 
density on CT have shown promise in early response evalu-
ation and in predicting long-term outcomes in patients with 
advanced GISTs treated with imatinib. Results from Choi 
and colleagues indicated that tumor size determined using 
the sum of the longest dimensions and the RECIST defini-
tions for a significant change were not reliable and under-
estimated the tumor response to imatinib during the early 
post-treatment stage in patients with metastatic GISTs. The 
mean tumor density, however, decreased significantly 2 
months after treatment compared with pretreatment val-
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ues. Moreover, evaluation using a combination of tumor 
size, tumor density, and absence or presence of tumor nod-
ules and tumor vessels was a better indicator of the tumor 
response to imatinib than tumor density alone [27]. 
Choi and associates evaluated a series of 40 patients 
treated with imatinib for recurrent or metastatic GISTs who 
had undergone both PET and CT evaluation to determine 
the CT findings that could differentiate those who had a 
good response by PET and those who did not [30]. They 
found that a decrease in tumor size of ≥10% or a decrease in 
tumor density of ≥15% identified 97% of good responders 
by PET and none of the seven poor responders [30]. They 
also demonstrated that response defined by these new CT 
criteria was correlated with longer TTP, whereas response 
by the RECIST was not [30].
Benjamin and associates confirmed the observations of 
Choi et al. [30] in a separate group of 58 patients and then 
evaluated all 98 patients by the RECIST and the Choi crite-
ria. All patients had pretreatment and follow-up CT scans. 
Disease-specific survival (DSS) and TTP were analyzed by 
response category. There were 45 (46%) good responders 
and 53 (54%) poor responders by the RECIST. In contrast, 
there were 81 (83%) good responders and 17 (17%) poor 
responders by the Choi criteria [31]. Despite the almost 
doubling of the response rate when patients were assessed 
by the Choi criteria versus the RECIST, patients with good 
responses by the Choi criteria on CT at 8 weeks after the 
start of treatment had equivalent DSS to that of patients 
with a CR or PR at any time by the RECIST. In addition, 
TTP and DSS were significantly correlated with the Choi 
response group, but not with the response group by the 
RECIST [31]. These results support the conclusion that the 
Choi response criteria, which incorporate tumor density 
and small changes in tumor size on CT, are more sensitive 
and accurate than the RECIST in assessing the response of 
GISTs to imatinib treatment. These results have been repro-
duced at other institutions; however, further validation 
needs to be completed [32].
Advances in CT technology are likely to further 
increase its usefulness for the evaluation of cancer thera-
pies. Greater numbers of detectors in CT scanners offer 
better three-dimensional reconstruction and volumetric 
measurement [33], but the lack of a sufficient number of 
centers with appropriate scanners to process data limits 
the organization of large-scale, multicenter clinical tri-
als. Automated collection and analysis of CT data are vital 
but not widely available, and manual data collection and 
analysis are expensive and time-consuming [34]. Another 
important limitation of CT methods is that heterogeneity 
of tumors (e.g., hypoxic regions) can confound volumetric 
measurements [35].
18FDG-PET
18FDG-PET can assess tumor glucose use with high repro-
ducibility. Following therapy, the decrease in glucose 
uptake correlates with a reduction in viable tumor cells. In 
contrast to CT, MRI, or ultrasound, PET imaging allows 
identification of responding and nonresponding tumors 
early in the course of therapy. PET imaging can easily dem-
onstrate changes in metabolic activity and indicate, some-
times within hours of the first treatment, whether or not a 
patient will respond to a particular therapy. 18FDG-PET has 
demonstrated efficacy for monitoring therapeutic response 
in a wide range of cancers, including breast, esophageal, 
lung, and head and neck cancers, and lymphoma [36, 37]. 
Effectiveness of 18FDG-PET
18FDG-PET is useful for determining the responses of 
GISTs to treatment with imatinib and may be superior 
to standard anatomic criteria for early evaluation of the 
responses of GISTs to targeted molecular therapies [38]. As 
noted above, evaluation using the RECIST may be poorly 
suited to these tumors because they may have a strong posi-
tive response to treatment (e.g., decreased FDG uptake, 
clinical improvement) without major shrinkage [27]. 
18FDG-PET scanning has also been shown to be a use-
ful method for prediction of outcomes in patients with 
high-grade extremity soft tissue sarcomas treated with che-
motherapy. Schuetze and colleagues evaluated 46 patients 
with high-grade localized sarcomas with 18FDG-PET. The 
maximum standardized uptake value (SUVmax) of tumors 
was measured before neoadjuvant chemotherapy and 
again prior to surgery. Resected specimens were examined 
for residual viable tumors. Patients with a baseline tumor 
SUVmax ≥6 and a <40% decrease in 18FDG uptake were at 
high risk for systemic disease recurrence, estimated to be 
90% at 4 years from the time of initial diagnosis. Patients 
whose tumors had a ≥40% decline in SUVmax in response to 
chemotherapy were at a significantly lower risk for recur-
rent disease and death after complete resection and adju-
vant radiotherapy (Fig. 1) [39]. 18FDG-PET results have also 
been shown to correlate closely with histologic responses 
of tumors to chemotherapy. Results from 36 patients with 
osteosarcoma or Ewing’s sarcoma–family tumors who 
received neoadjuvant therapy indicated that a good 18FDG-
PET response was concordant with a histologic response 
in 68%–69% of patients. In addition, a lower SUVmax after 
neoadjuvant chemotherapy (SUV2) was associated with 
better long-term outcomes in this small study cohort (the 4-
year PFS rate was 72% for SUV2 <2.5 versus 27% for SUV2 
≥2.5; p = .01 for all patients) [40].
Results from additional studies have demonstrated that 
18FDG-PET is useful for the staging of solid tumors and for 
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assessing responses to neoadjuvant therapy [41, 42]. Review 
of the results from 16 studies of patients with esophageal 
carcinoma indicated that the accuracy of 18FDG-PET in 
assessing response to treatment was similar to that for endo-
esophageal ultrasonography and significantly superior to 
that for CT. The staging value of 18FDG-PET was limited 
for the detection of locoregional metastases, but the tech-
nique was effective for the detection of distant lymphatic 
and hematogenous metastases [42]. 18FDG-PET has also 
been shown to be useful for monitoring results of therapy 
in patients with stage III non-small cell lung cancer [41] and 
for identification of progressing lesions and for detecting 
flares in tumor lesions that were previously under control 
[43, 44].
New positronic substrates will likely expand the utility 
of PET [44]. The most widely used PET tracer for osteosar-
coma is 18FDG. The other clinical PET tracer with reported 
utility for osteosarcoma imaging is 18F-fluoride ion. 18F-
labeled monoclonal antibodies, 18F-fluoromisonidazole, 
18F-labeled arginine–glycine–aspartic acid (RGD)-con-
taining glycopeptide, 3H-thymidine, 13N-methionine, and 
PET of p53 transcriptional activity in osteosarcoma are all 
being investigated [44].
18FDG-PET Issues
While 18FDG-PET has clearly been demonstrated as an 
important advance for staging, prognosis, and evaluation 
of treatment responses in patients with solid tumors, this 
technique does have significant limitations. These include 
inability to characterize lesions <1 cm in diameter, dif-
ficulty in distinguishing benign post-therapy or unrelated 
Figure 1. Kaplan–Meier plot demonstrating a significantly 
higher risk for metastatic disease recurrence in patients with 
a pretreatment sarcoma maximum standardized uptake value 
(SUVmax) ≥6 and poor metabolic response to neoadjuvant che-
motherapy (p = 0.004) [43].
inflammatory responses from the effects of treatment on 
tumors, and variability in signal acquisition across instru-
ments and in interpretation and analysis among readers 
[26]. Multi-institutional studies using 18FDG-PET need to 
consider the potential impact of this variability on overall 
results. It has also been noted that 18FDG-PET evaluations 
can be very subjective, and that even SUV is only a semi-
quantitative measure [45]. In addition, static 18FDG uptake 
indices alone may not enable adequate differentiation 
between benign and malignant lesions. While quantitative 
dynamic imaging may provide more helpful information, 
it is more labor-intensive and costly. Another limitation of 
18FDG-PET is variable 18FDG uptake in normal structures 
and sites of inflammation caused by infection or foreign 
bodies, leading to false-positive results [46].
MRI
Ongoing efforts are developing more powerful methods 
for automated classification of MRI spectra, based on the 
acquisition of large datasets of tumor spectra and use of dif-
fusion- and perfusion-weighted imaging. These methods are 
useful for distinguishing between tumors and abscesses and 
for predicting responses to radiotherapy, respectively [47].
Magnetic resonance spectroscopy may predict response 
in a manner analogous to PET [48]. Both of these methods 
permit imaging of the entire body and combine functional 
and anatomical information. 18FDG-PET and MRI spec-
troscopy are valuable techniques for monitoring tumor 
response in patients undergoing chemo- and radiotherapy, 
particularly when evaluating early responses. In contrast, 
MRI is particularly useful for assessing metastasis and 
infiltration of bone marrow and the central nervous system. 
Dynamic contrast-enhanced MRI (DCE-MRI) is a new 
imaging method for assessing the physiological state of 
tumor vascularity in vivo. This method uses available imag-
ing techniques and contrast agents and assays the kinetics of 
tumor enhancement during bolus i.v. contrast administra-
tion [49]. DCE-MRI has been shown to be useful for detect-
ing microvascular changes in tumors in response to isolated 
limb perfusion within 24 hours of treatment in experimental 
animals [50] and for correctly predicting tumor responses 
to therapy in a small cohort of 12 patients with histologi-
cally proven high-grade soft tissue sarcoma [51]. DCE-MRI 
correctly predicted tumor response in 8 of 10 evaluable 
patients. Early rapidly progressive enhancement was corre-
lated histologically with residual viable tumors, and late and 
gradual, or absence of, enhancement was correlated with 
necrosis, predominantly centrally located, or granulation 
tissue [51]. These preliminary results show that DCE-MRI 
offers the potential for noninvasive monitoring of responses 
to isolated limb perfusion in soft tissue sarcomas.
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Future Directions/Consensus
The results summarized in this review support the conclu-
sion that the RECIST and the WHO criteria for evaluation of 
response in solid tumors need to be replaced by alternative 
endpoints. While these criteria have been useful, change 
is mandated in order to provide more rapid assessment of 
tumor responses and to reflect the advances in imaging 
technology that have occurred over the past decade. Pro-
spective trials are needed to compare new response criteria 
with established endpoints and to validate imaging-based 
response rates as surrogates for traditional endpoints. New 
approaches developed for evaluation of sarcomas should 
subsequently be assessed in other tumor types. However, 
the underlying biology of tumors may impact the applica-
bility of imaging-based criteria, and response kinetics and 
landmarks may vary among tumor types. In addition, alter-
native response criteria may have different prognostic val-
ues for cytotoxic versus cytostatic therapies.
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